Is Aspirin Safe for Fatty Liver Disease?

Is aspirin safe for fatty liver disease? For most people with simple hepatic steatosis, low-dose aspirin is generally considered safe under medical supervision, but the answer depends significantly on the stage and severity of your liver condition. Fatty liver disease, including NAFLD and MASLD, is common in the UK, and many affected individuals also have cardiovascular conditions for which aspirin is prescribed. Understanding the risks, current UK guidance, and safer alternatives is essential before taking or continuing aspirin when you have a liver condition.

Is aspirin safe to take if you have a fatty liver?

Low-dose aspirin is generally safe in simple fatty liver disease without significant fibrosis or cirrhosis, but must be used under medical supervision and is not recommended for self-initiated primary cardiovascular prevention.

For most people with simple fatty liver disease (hepatic steatosis) who do not have significant liver inflammation or cirrhosis, low-dose aspirin is generally considered safe when used appropriately and under medical supervision. Fatty liver disease, which includes non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common liver conditions in the UK, with NHS data indicating it affects a substantial proportion of the adult population.

Aspirin belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) and works by irreversibly inhibiting the cyclo-oxygenase (COX-1 and COX-2) enzymes, reducing the production of prostaglandins and thromboxane A2. This gives it analgesic, anti-inflammatory and antiplatelet properties. At low doses, typically 75 mg daily in the UK as listed in the British National Formulary (BNF), it is widely prescribed for cardiovascular protection in people with established cardiovascular disease.

It is important to note that low-dose aspirin should not be started for primary prevention of cardiovascular disease without a confirmed clinical indication and explicit advice from a clinician, in line with current UK guidance.

Emerging observational research has suggested that regular low-dose aspirin use may be associated with a reduced risk of liver fibrosis progression and hepatocellular carcinoma in people with chronic liver disease.^[7][8] These findings come from cohort and registry studies and are not yet practice-changing; they do not form the basis of formal UK clinical recommendations and should not be taken as a reason to start aspirin independently.

If you have been diagnosed with fatty liver disease and are considering taking aspirin, whether for pain relief or cardiovascular reasons, it is important to discuss this with your GP before starting or continuing use. The appropriateness of aspirin depends heavily on the stage and severity of your liver condition, as well as your overall health profile.

What does current UK guidance say about aspirin and liver disease?

UK guidance does not prohibit low-dose aspirin in fatty liver disease, but the BNF advises caution in hepatic impairment and contraindicates it in severe hepatic impairment due to elevated bleeding risk.

Current UK guidance does not specifically prohibit low-dose aspirin in people with fatty liver disease, but it does urge caution in those with more advanced liver conditions, particularly cirrhosis. NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management) focuses primarily on lifestyle modification, weight management and cardiovascular risk reduction, and does not address aspirin use directly in this context.^[2] In UK primary care practice, liver fibrosis is typically staged using tools such as the FIB-4 index or the Enhanced Liver Fibrosis (ELF) test, as recommended by NICE NG49, before decisions about ongoing medications are made. NICE guidance on secondary prevention of cardiovascular disease supports the use of low-dose aspirin in people with established cardiovascular disease, a group that significantly overlaps with those who have NAFLD or MASLD.

The BNF advises that aspirin should be used with caution in patients with hepatic impairment, and that it should be avoided in severe hepatic impairment.^[4] This is because the liver plays a central role in producing clotting factors, and in advanced disease, aspirin's antiplatelet effect can compound an already elevated bleeding risk. The UK aspirin 75 mg gastro-resistant tablet Summary of Product Characteristics (SmPC), available on the electronic Medicines Compendium (emc), lists hepatic impairment as a precaution and severe hepatic impairment as a contraindication.^[5] Simple fatty liver, without significant fibrosis or cirrhosis, does not typically constitute clinically significant hepatic impairment in the pharmacological sense.

For people who require aspirin for a confirmed cardiovascular indication, UK clinicians generally continue it even in the presence of fatty liver disease, provided there is no evidence of advanced fibrosis, portal hypertension or coagulopathy. Regular review by a GP or specialist is advisable to reassess the risk-benefit balance as liver disease can progress over time.

Who should avoid aspirin if they have liver problems?

People with decompensated cirrhosis, portal hypertension, or significant coagulopathy should avoid aspirin, as should those under 16 years of age, pregnant individuals, and those on concurrent anticoagulants.

People with severe or decompensated liver disease should avoid aspirin, as the risks of serious bleeding and further liver injury are substantially increased in this group. Decompensated cirrhosis, characterised by complications such as ascites, hepatic encephalopathy, variceal bleeding or jaundice, represents a state of significantly impaired liver function where aspirin is contraindicated according to its UK SmPC.

Several specific groups with liver problems warrant particular caution:

• People with cirrhosis: The liver's reduced capacity to synthesise clotting factors, combined with aspirin's antiplatelet effect, creates a compounded bleeding risk, particularly from oesophageal varices. British Society of Gastroenterology (BSG) and European Association for the Study of the Liver (EASL) guidance generally advises avoiding NSAIDs, including aspirin, in people with cirrhosis or portal hypertension due to bleeding and renal risks; specialist advice should be sought.

• Those with portal hypertension: Elevated pressure in the portal venous system increases the risk of gastrointestinal bleeding, which aspirin can exacerbate.

• Individuals with a history of peptic ulcer disease or gastrointestinal bleeding: Aspirin irritates the gastric mucosa and inhibits protective prostaglandins, raising the risk of ulceration and haemorrhage.

• People taking other anticoagulants or antiplatelet agents: Combining aspirin with warfarin, direct oral anticoagulants (DOACs) or other NSAIDs significantly amplifies bleeding risk.

• Those with alcohol-related liver disease: Ongoing alcohol use alongside aspirin further increases gastrointestinal bleeding risk and may worsen liver inflammation.

• Children and young people under 16 years of age: Aspirin is contraindicated in those under 16 due to the risk of Reye's syndrome, a rare but serious condition affecting the liver and brain.^[5][6] This applies regardless of liver status.

• People who are pregnant: Aspirin should be avoided in pregnancy, particularly in the third trimester, unless specifically directed by a clinician. Anyone who is pregnant or planning a pregnancy and has liver disease should seek specialist advice before taking aspirin.

People with intermediate-stage liver disease, such as significant fibrosis (F2 to F3 on standard scoring systems) but not yet cirrhosis, occupy a grey area where the decision should be made on an individual basis by a GP or hepatologist. If you are unsure about the stage of your liver disease, your GP can arrange appropriate investigations, including liver function tests, a FIB-4 calculation, ELF test or FibroScan (liver elastography), to help clarify the picture before any decision about aspirin is made.

What side effects should you watch for when taking aspirin with a fatty liver?

The most important side effects to monitor are gastrointestinal bleeding, stomach pain, unusual bruising, and any worsening of liver symptoms such as jaundice or abdominal swelling.

The most clinically important side effects to monitor when taking aspirin alongside fatty liver disease relate to bleeding and gastrointestinal irritation, both of which can be more consequential when liver function is already compromised. Aspirin inhibits thromboxane A2-mediated platelet aggregation irreversibly for the lifetime of the platelet (approximately 7 to 10 days), meaning even a single dose has a prolonged antiplatelet effect.^[1][4]

Key side effects and warning signs to be aware of include:

• Gastrointestinal bleeding: Symptoms include vomiting blood or material that looks like coffee grounds, black or tarry stools (melaena), or fresh rectal bleeding. Vomiting blood or passing large amounts of blood requires an immediate 999 call or attendance at an emergency department. Other symptoms of gastrointestinal bleeding should prompt urgent contact with your GP or NHS 111.

• Stomach pain or indigestion: Aspirin can cause gastric irritation, ulceration and dyspepsia. A gastroprotective agent such as a proton pump inhibitor (PPI), for example omeprazole, is recommended by UK prescribers for patients at higher gastrointestinal risk, including those aged 75 or over, those with a history of peptic ulcer or gastrointestinal bleeding, and those taking concomitant anticoagulants or SSRIs. This is a risk-based decision rather than routine co-prescription for everyone taking aspirin.

• Unusual bruising or prolonged bleeding: Because aspirin impairs platelet function, minor cuts or injuries may bleed for longer than expected.

• Worsening liver symptoms: Although aspirin is not typically hepatotoxic at low doses, any new or worsening jaundice, abdominal swelling or confusion in someone with known liver disease should prompt urgent medical review.

• Allergic reactions: Aspirin hypersensitivity, including aspirin-exacerbated respiratory disease, can occur and is unrelated to liver status.

If you suspect a side effect from aspirin, report it to your GP and consider submitting a report via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which accepts reports from both patients and healthcare professionals.

Safer pain relief options for people with fatty liver disease

Paracetamol at recommended doses is the preferred first-line analgesic for fatty liver disease; oral NSAIDs such as ibuprofen are generally best avoided due to risks of gastrointestinal bleeding and hepatic deterioration.

Paracetamol, used at the recommended dose, is generally considered the first-line analgesic for people with fatty liver disease who do not have advanced liver impairment, and is often preferable to aspirin or other NSAIDs for routine pain relief. This may seem counterintuitive given paracetamol's well-known association with liver toxicity in overdose, but at therapeutic doses it is metabolised safely by most people with fatty liver. The BNF lists the standard adult dose as up to 4 g per day in adults without significant liver disease.^[9] In people with significant hepatic impairment, the dose should be reduced and individualised on the advice of a clinician or pharmacist, as the threshold for toxicity may be lower; a commonly applied caution is to limit intake to no more than 2 g per day, though this should be confirmed with your GP or specialist rather than applied as a fixed rule. Alcohol use alongside paracetamol also increases hepatotoxicity risk and should be avoided.

Other pain relief considerations for people with fatty liver disease include:

• Topical NSAIDs: Preparations such as diclofenac gel or ibuprofen gel applied directly to the skin deliver a localised anti-inflammatory effect with lower systemic absorption than oral NSAIDs, reducing the risk of gastrointestinal and hepatic side effects.^[10] Some systemic absorption does occur, so caution is still advisable in advanced liver disease.

• Codeine or weak opioids: These may be used short-term under medical supervision, though they carry their own risks in liver disease, including accumulation and encephalopathy in advanced cases.

• Physiotherapy and non-pharmacological approaches: For musculoskeletal pain, exercise, physiotherapy and heat or cold therapy can reduce reliance on analgesics altogether.

Oral NSAIDs such as ibuprofen and naproxen are generally best avoided in people with significant liver disease due to risks of gastrointestinal bleeding, fluid retention, renal impairment and potential worsening of hepatic function. These risks are particularly pronounced in people with cirrhosis. Always discuss pain management options with your GP, who can tailor advice to your specific liver stage and overall health. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations with prescriber review and pharmacist support, where clinically appropriate treatment options may be discussed.

Scientific References

1. The mechanism of action of aspirin.
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
3. Cardiovascular disease risk assessment and prevention – BNF/NICE.
4. Aspirin | Drugs – BNF/NICE.
5. Aspirin 75 mg Gastro-Resistant Tablets – Summary of Product Characteristics (emc).
6. Aspirin: medicine for pain relief or preventing blood clots.
7. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.
8. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in NAFLD patients.
9. Paracetamol | Drugs – BNF/NICE.
10. NSAIDs – NHS.
11. Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment – GOV.UK Drug Safety Update.

Frequently Asked Questions